3E Bioventures Capital also known as Bencao Ziben focuses on healthcare. Core members of the firm are trained in biomedical fields and have healthcare industry experience and have investment or entrepreneur experience in China. Areas they invest in include drug, device, diagnostics, healthcare IT and medical services. 3E Bioentures manages both RMB and US Dollar funds and invests in early and growing stage companies in China and overseas.
In 2017 3E led Series A funding for Oncolmmune, a clinical stage biopharmaceutical company working on immunotherapies for cancer, inflammation and autoimmune diseases.
Founding partner of 3E Dr. Karen Liu has experience in healthcare investment from previous positions at Kaiwu Capital and CRCI Capital. Liu previously founded Shenogen Pharma, a company developing liver cancer therapeutics. Liu has a B.S. from Cornell University, Master of Medical Sciences degree from Harvard University and a PhD in Immunology from Harvard University. She also has an EMBA degree from Chungkong Graduate School of Business in China.